Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 10/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17853010 | 0.95 | GPR183 (0.86) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17856080 | 0.93 | GPR183 (0.91) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17954166 | 0.89 | GPR183 (0.69) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17856079 | 0.88 | GPR183 (1.00) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17853008 | 0.85 | GPR183 (0.87) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL16600066 | 0.83 | GPR183 (0.81) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17853003 | 0.83 | GPR183 (0.78) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17856076 | 0.81 | GPR183 (1.00) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17938686 | 0.81 | GPR183 (0.80) | GPR183KMT2AMEN1HRH4HRH3 | |
| SCHEMBL17954141 | 0.80 | GPR183 (0.65) | GPR183KMT2AMEN1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | Sanford Burnham Prebys Medical Discovery Institute | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | HAVCR2, BIRC2, ESR2 | GPR183 17/4885KMT2A 1255/4885MEN1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.